DWA
CRSP icon

Delos Wealth Advisors’s CRISPR Therapeutics CRSP Stock Holding History

Delos Wealth Advisors’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-3
Closed – – 446
2021
Q3 		$0 Buy
+3
New +$377 ﹤0.01% 219

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Delos Wealth Advisors's CRSP Position: Q4 2021 in Review

Delos Wealth Advisors sold out of CRISPR Therapeutics (CRSP) in Q4 2021, closing a stake of 3 shares.

Delos Wealth Advisors first reported a position in CRSP in Q3 2021 and held it in 1 quarter. The position peaked at $0 in Q3 2021. 446 funds tracked by Wall St. Rank hold CRSP as of Q4 2021.

  • Delos Wealth Advisors reported no remaining CRISPR Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Delos Wealth Advisors sold 3 CRISPR Therapeutics shares in Q4 2021.
  • Delos Wealth Advisors first reported a position in CRISPR Therapeutics in Q3 2021 and held it in 1 quarter.
  • Delos Wealth Advisors's CRISPR Therapeutics position peaked at $0 in Q3 2021.
  • 446 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2021.

Based on Delos Wealth Advisors's 13F filing for Q4 2021, filed 14 Feb 2022.